These data support previous hypotheses that AMPs can act against cancer, including colon cancer, through a variety of mechanisms of action, and the modulation of miR-663a could be just one factor inducing the negative effect on cancer by the administration of AMPs. The gene discussed is ADSL; the disease is colonic neoplasm.